Chongkundang Holdings종근당홀딩스

Chongkundang Holdings trades near book value after a steep fall, with profit recovering on a modest revenue base and a 3.9% dividend yield.

Chongkundang Holdings is a holding company whose income comes mainly from subsidiaries in pharmaceuticals, health foods and real estate/elderly care. Trailing results to H1 2026 show revenue of about ₩962B, operating income of ₩56B and net income of ₩54B, with borrowings of ₩598B against cash of ₩45B. The share price is ₩35,600, down 24.4% over one year and close to its 52-week low of ₩35,450.

What stands out

• Trailing operating margin is 5.8%, up from 3.7% in 2024 and 6.1% in 2025 on a roughly flat revenue base, so profitability is not clearly improving over the full year.
• Valuation looks low on the numbers given: P/E of 3.3, P/B of 0.3 and a 3.9% dividend yield, though the fair value model's base case of ₩61,233 and bull case of ₩309,562 are very far apart and the bear case is shown as zero, so the model output is not a reliable guide.
• Liabilities are 87.2% of equity and borrowings are large relative to cash, which is a balance sheet point to keep in mind.
• Recent filings include a suspension-related material matters report for a subsidiary, first filed in August and corrected in late September, plus an amended half-year report dated 12 October.
• Foreign ownership rose slightly to 3.6% from 3.2% over 60 days, while 20-day flows show retail buying and foreign and institutional selling. No news headlines were provided in the data.

What to watch

• Details and impact of the subsidiary business suspension mentioned in the material matters reports, which the data does not explain.
• The amended half-year report and the next full-year results, to see whether margins and cash flow hold up.
• Whether the share price stays near its 52-week low; the data does not include analyst ratings or forecasts.